4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity
09 avr. 2024 08h05 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity Long-Term Partnership Agreed with Beacon Therapeutics for Clinical and Commercial AAV...
4BIO Capital Strengthens Advisory Board and Investment Team
11 mars 2024 10h00 HE
|
4Bio Capital
Press Release 4BIO Capital Strengthens Advisory Board and Investment Team Industry veteran and former CEO of Vifor Pharma Abbas Hussain and world leading vectorology expert and LogicBio...
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04 janv. 2024 07h00 HE
|
4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04 janv. 2024 02h00 HE
|
4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...
4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases
16 mai 2023 08h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases Series A follows initial seed...
4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics
16 nov. 2022 08h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics 16 November 2022 London & New York – 4BIO Capital (“4BIO” or “the Group”), an international...
4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing
07 juin 2022 08h30 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater Philadelphia – 4BIO Capital...
4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science
06 juin 2022 03h00 HE
|
4Bio Capital
Press Release 4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science Financing reflects the potential of mitochondrial therapy to restore cellular...
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
10 janv. 2022 13h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration will combine...
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
10 janv. 2022 13h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration will combine...